- BioNTech reported 1Q loss per share of EU1.31, higher than the estimated loss per share of EU1.13.
- The revenue for 1Q was EU187.6 million, which was lesser than the estimate of EU305 million.
- Research and Development expenses increased by 52% y/y, amounting to EU507.5 million, less than the estimated EU595.1 million.
- Operating loss was EU507.2 million, compared to a profit of EU654.4 million y/y, just above the estimated loss of EU506.7 million.
- Purchases of property, plant and equipment increased by 29% y/y to EU58.5 million, less than the better estimations for the cost, EU105 million.
- Cash and cash equivalents was EU16.94 billion, higher than the estimated EU16.53 billion.
- BioNtech reiterated their forecast for R&D expenses which still sees between EU2.40 billion to EU2.60 billion, estimate was EU2.43 billion.
- Expected SG&A expense is estimated to be in the range of EU700 million to EU800 million, close to the estimate of EU736.1 million.
- Capital expenditure is still expected to be in the range of EU400 million to EU500 million.
- BioNTech anticipates group revenues for the full 2024 financial year to be between €2.5 billion to €3.1 billion.
BioNTech on Smartkarma
Analysts on Smartkarma, like Baptista Research, are taking a bullish stance on BioNTech. In their report titled “BioNTech SE: How Its Strengthened Pipeline & Portfolio Is Changing The Game!”, they highlight the biotechnology major’s recent progress. BioNTech’s advancements in clinical pipelines, technology platforms, and strategic initiatives have caught the attention of analysts, signaling a positive outlook for the company.
Baptista Research‘s first report on BioNTech emphasizes the company’s successful execution of key strategies and improvements in various aspects of its operations. With a focus on the company’s recent earnings and developments, analysts are optimistic about BioNTech’s future prospects in the biotechnology industry. Stay tuned for more insights from independent analysts on Smartkarma as they continue to track and evaluate BioNTech’s performance.
A look at BioNTech Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 1 | |
| Growth | 5 | |
| Resilience | 5 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, BioNTech shows a promising long-term outlook. With a high Growth score of 5, the company is poised for significant expansion and development in the future. Additionally, BioNTech scores well in Resilience, indicating its ability to weather uncertainties and challenges in the market. The company’s strong emphasis on innovation and progress in the field of biotechnological solutions bodes well for its future prospects.
While BioNTech demonstrates strengths in Value with a score of 4, its Dividend score of 1 suggests a low focus on providing dividends to shareholders. However, the company’s overall momentum is considered moderate with a score of 3. BioNTech’s dedication to providing treatments for cancer patients’ tumors showcases its commitment to making a meaningful impact in the healthcare industry on a global scale.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
